RESEARCH SHOWS MEMANTINE CAN TREAT SICKLE CELL DISEASE
+
THE NEED FOR MEMANTINE
The world needs a treatment for sickle cell diseases that is accessible, effective and cheap.
In 2021, an estimated 7.74 million people were living with sickle-cell disease globally
with sub-Saharan Africa accounting for nearly 80% of global cases
+
WHAT IS MEMANTINE?
Originally used for Alzheimer’s disease Memantine protects blood cells from the inside out to prevent sickling.
MEMANTINE: Cost per dose: 30 cents
Easy to
store
Easy to
dose
Easy to Transport
+
MEMANTINE BENEFITS
A recent MeMAGEN clinical trial found that memantine was safe and well tolerated in both children and adults with SCD with only mild side effects reported. In children, the results were particularly encouraging, showing a significant reduction in the number of days spent in hospital.
The study also found improvements in red blood cell health. Memantine reduced potassium “leakage” and improved cell hydration, an important outcome, as dehydration causes these cells to sickle and block blood flow. Memantine may also help address the cognitive difficulties often associated with SCD.
Memantine is a drug that has been used for 30 years in the treatment of Alzheimer’s.
We know that it is safe and that it is effective in the management of Sickle Cell Disease. So why aren’t we using Memantine?
+
READ THE EVIDENCE
MeMAGEN: A Phase IIa/IIb open‐label trial of memantine testing safety and tolerability in sickle cell patients
EXPERIENCE HOW MEMANTINE WORKS
FOR INFORMATION ON TRYING MEMANTINE